Bezos’ AI startup Prometheus raises $12B, valued at $41B - eciks.org

· Source: Series A" OR "Series B" OR "Series C" AI startup via Google News · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Emerging Technologies & Innovation, Robotics & Autonomous Systems · Depth: Fundamental Awareness, quick

Summary

Jeff Bezos' AI startup, Prometheus, secured \$12 billion in Series B funding on June 11, 2026, elevating its valuation to \$41 billion and establishing it as a leading private AI venture globally. Co-led by Bezos and Vik Bajaj, the industrial AI firm, launched in November 2025 with \$6.2 billion in seed funding, now boasts over \$18 billion in total capital raised and approximately 150 employees. Prometheus aims to develop an "artificial general engineer" capable of automating the design and manufacturing of intricate physical systems, from jet engines to drug compounds. This initiative marks Bezos' return to an active operating role, focusing on "physical AI" to apply deep learning to real-world industrial processes. The substantial investment from firms like JPMorgan Chase, Goldman Sachs, and BlackRock reflects strong investor confidence in the physical AI sector's potential to redefine industrial productivity.

Key takeaway

For investors evaluating industrial technology, Prometheus' rapid \$41 billion valuation and focus on "physical AI" signal a significant shift in automation. You should assess how AI-driven design and manufacturing could disrupt traditional engineering sectors, considering potential long-term impacts on productivity and market leadership. This venture highlights the increasing capital flow into AI solutions beyond consumer applications.

Key insights

Prometheus is pioneering "physical AI" to automate complex industrial design and manufacturing with an "artificial general engineer."

Principles

Method

Prometheus is building software to automate the design and manufacturing of complex physical systems, applying deep learning to engineering, manufacturing, and drug design processes.

In practice

Topics

Best for: Investor, Executive, Director of AI/ML

Related on AIssential

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Series A" OR "Series B" OR "Series C" AI startup via Google News.